GlassScriptPhysician profile
Rekha Kalidindi
NPI 1750678942
$2,611.97
in general payments reported to CMS, 2019-2025
27 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $310 · 2024: $977 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $370.22 | 2023-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $319.16 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $230.49 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $229.86 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.69 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $134.31 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $122.31 | 2023-2025 | |
| Corium, LLC | $108.89 | 2023-2025 | Azstarys |
| Inspire Medical Systems, INC. | $107.66 | 2023-2025 | Inspire |
| Abbvie INC. | $88.04 | 2025 | |
| Hologic Sales and Service, LLC | $88.03 | 2025 | Aptima |
| Amgen INC. | $76.53 | 2024-2025 | Repatha, Krystexxa, Otezla |
| Astellas Pharma US INC | $74.26 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $70.83 | 2024-2025 | Zoryve |
| Saluda Medical Americas, INC. | $68.86 | 2024 | Evoke |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $52.94 | 2023-2025 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $31.31 | 2024 | |
| Merck Sharp & Dohme LLC | $30.61 | 2024-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Abbott Laboratories | $30.00 | 2024 | Proclaim |
| Ars Pharmaceuticals Operations, INC. | $29.27 | 2025 | Neffy |
| Sanofi Pasteur INC. | $25.87 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.26 | 2025 | |
| Bioventus LLC | $23.14 | 2024 | Exogen Ultrasound Bone Healing System |
| Ultragenyx Pharmaceutical INC. | $21.12 | 2024 | Crysvita |
| Cranial Technologies, INC | $18.99 | 2023 | Doc Band |
| Alk-Abello, INC | $16.96 | 2023 | Grastek, Ragwitek, Odactra |
| Millicent US INC | $14.36 | 2025 | Femlyv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rekha Kalidindi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.